Xianle Health (300791): Orderly business development, profit improvement can be expected
Dongfang Wealth Securities released a research report on April 26 stating that it gave Xianle Health (300791.SZ) an increase in holdings rating. The main reasons for the rating include: 1) the company published its annual report for the year 23 and the qu
Xianle Health (300791) Company Review: R&D Empowers Global Business Continued Expansion
Xianle Health (300791): 2024Q1 revenue is in line with expectations, and the level of endogenous profit increased beyond expectations
Pacific released a research report on April 23 stating that Xianle Health (300791.SZ) was given a purchase rating, and the target price was 45.05 yuan. The main reasons for the rating include: 1) high revenue growth for the full year of 2023; 2) the endog
Xianle Health (300791): Continued high growth in Q4+Q1, focus on BF's profit improvement
Xianle Health (300791): Endogenous business continues to improve, and BF gradually improves
Guolian Securities released a research report on April 22 stating that it gave Xianle Health (300791.SZ) a purchase rating, and the target price was 44.18 yuan. The main reasons for the rating include: 1) the high increase in revenue and profit, and the m
Xianle Health (300791): 23 years ended successfully and continued to promote major customer development strategies
Xianle Health (300791): Endogenous business focuses on BF's profit improvement
Xianle Health (300791): Long-term and short-term logical resonance valuations are expected to increase
Xianle Health (300791): The profit margin of leading health food foundries is gradually expanding
Xianle Health (300791): Consumers pay more attention to health, and the performance of leading nutritional and health food CDMO companies is expected to grow steadily
Xianle Health (300791) Company In-depth Research: Accelerating endogenesis & BF improving the steady progress of functional food leaders
Xianle Health (300791): US channel inventory removal basically ends, established an inflection point
Xianle Health (300791): Endogenous business performance is impressive, and the advantages of global layout are expected to gradually become apparent
Xianle Health (300791): Both endogenous and external extensions improved profits exceeded expectations
Xianle Health (300791): Outstanding performance in Q3 and continued recovery can be expected
Xianle Health (300791): The trend of quarterly improvement is obvious, and the business outlook for next year is positive
Xianle Health (300791): Revenue accelerates, development, organizational vitality is fully stimulated
No Data